Nonnucleoside Reverse Transcriptase Inhibitor Resistance

Summary: Although understanding of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance is less clearly established than that of other classes of antiretroviral drugs, certain facts have been established. The treatment‐associated genetic mutation profiles of the available NNRTIs have been mapped, and resistance has been found to develop rapidly after initiation of NNRTI therapy. Despite the chemical diversity of the NNRTIs, cross‐resistance among agents of this class is nearly universal. Although the viral replicative capacity (“fitness”) of NNRTI‐induced viral variants has not been extensively studied, available data suggest that NNRTI‐selected mutations confer little damage to viral fitness, and thus a single point mutation produces a strain that is both resistant and fit. Furthermore, with continued therapy, viral evolution persists, creating species with greater numbers of mutations and higher level phenotypic resistance. Taken together, these facts suggest that continued use of NNRTIs after emergence of resistance will produce variants of complex mutational patterns that limit future treatment options, and, therefore, strong consideration should be given to discontinuing NNRTIs after virologic failure is confirmed. This article describes the scientific literature establishing the efficacy and limitations of NNRTI therapy and attempts to define a role for this class of drug in the long‐term treatment of HIV‐1 disease.

[1]  C. Petropoulos,et al.  Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients , 2000, AIDS.

[2]  D. Katzenstein,et al.  Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. , 2000, The Journal of infectious diseases.

[3]  L. Mofenson,et al.  Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission , 2000, AIDS.

[4]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[5]  K. Hertogs,et al.  Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy. , 2000, The Journal of infectious diseases.

[6]  D. Richman,et al.  Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. , 2000, The Journal of infectious diseases.

[7]  D. Katzenstein,et al.  Rapid Communication: Efavirenz‐ and Adefovir Dipivoxil‐Based Salvage Therapy in Highly Treatment‐Experienced Patients: Clinical and Genotypic Predictors of Virologic Response , 2000, Journal of acquired immune deficiency syndromes.

[8]  R. Shafer,et al.  Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260) , 2000, Antimicrobial Agents and Chemotherapy.

[9]  S. Hammer Antiretroviral Resistance Testing Comes of Age , 2000, Antiviral therapy.

[10]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[11]  Alan S. Perelson,et al.  Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.

[12]  E. Rosenberg,et al.  Reduced antiretroviral drug susceptibility among patients with primary HIV infection. , 1999, JAMA.

[13]  R. Bambara,et al.  The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5′-End- and DNA 3′-End-Directed RNase H Activities , 1999, Journal of Virology.

[14]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[15]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[16]  L. Demeter,et al.  HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[17]  D. Richman,et al.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.

[18]  M. Niu,et al.  Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection , 1996, Annals of Internal Medicine.

[19]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[20]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[21]  I. Chen,et al.  A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. McCutchan,et al.  Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. , 1993, The New England journal of medicine.

[23]  B. Larder 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors , 1992, Antimicrobial Agents and Chemotherapy.

[24]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[25]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.